Reformulary Group signs MedReleaf as first Licensed Producer for new medical cannabis formulary

Partnership with company’s Cannabis Standard will help employers manage medical cannabis coverage


TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Reformulary Group, Canada’s leading, independent drug plan management company, today announced it has signed MedReleaf as its first Licensed Producer of medical cannabis.

The agreement will provide subscribers of Reformulary’s Cannabis Standard – the first cannabis formulary in Canada – with preferred pricing options and will support the development of a database that captures real-world patient-reported data. This partnership is a major step for Canadian employers looking to navigate the process of covering medical cannabis.

“Our partnership with MedReleaf will ensure employers and individuals using Cannabis Standard receive evidence-based advice related to the use of medical cannabis, and high-quality medical cannabis at a preferred price,” said Helen Stevenson, Reformulary Group founder and CEO. “As cannabis becomes more mainstream in the medical world, it is critical that employers that choose to cover cannabis have expert guidance on how to include cannabis in their benefit plans.”

“The creation of the very first cannabis formulary in Canada demonstrates the evolution of medical cannabis and its broader acceptance as a viable treatment option and will enable employers to add medical cannabis on their benefits plans with greater confidence.” said Jason Fleming, Vice President HR MedReleaf. “Partnering with Reformulary Group is an opportunity for us to work collaboratively to enhance the understanding and facilitate the incorporation of medical cannabis into the workplace.”

This agreement comes on the heels of Reformulary Group’s announcement last week that it had created the Cannabis Formulary Committee, an expert group designed to review the best available evidence for the use of medical cannabis.

About Reformulary Group
Reformulary Group is a healthcare company, founded in Toronto in 2011. The company’s most notable innovation is its proprietary formulary – the Reformulary® – which it sells on a subscription basis to Canadian employers.

About MedReleaf
Canada’s most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis.  Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit or follow @medreleaf

Media Contact:
Alex Cerelli, MAVERICK
O: 416.640.5525 x 238
M: 905.864.5530